Matches in SemOpenAlex for { <https://semopenalex.org/work/W2265434527> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2265434527 endingPage "TPS233" @default.
- W2265434527 startingPage "TPS233" @default.
- W2265434527 abstract "TPS233 Background: Until recently, patients with metastatic renal cell carcinoma (mRCC) had few treatment options given the low response rate associated with chemotherapy and cytokine treatment. An improved understanding of the molecular basis of RCC has led to the development of targeted therapies that have shown clinical benefit in patients with metastatic disease. Everolimus is an oral inhibitor of the mammalian target of rapamycin (mTOR), a key regulator of cell growth and proliferation, cellular metabolism, and angiogenesis that is aberrantly activated in RCC. In the pivotal RECORD-1 study, everolimus monotherapy prolonged progression-free survival (PFS) vs placebo in patients with clear cell mRCC whose disease had progressed on vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy, and everolimus is now approved for this indication. The EVERMORE (Everolimus as Monotherapy Treatment for Patients with Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma) trial will evaluate the efficacy and safety of everolimus monotherapy in patients with metastatic recurrent and/or unresectable RCC without prior systemic therapy other than cytokine therapy. Methods: EVERMORE is an open-label, multicenter, single-arm phase II trial. Up to 80 adult patients with metastatic, recurrent, or unresectable RCC of any MSKCC prognosis and histologic or cytologic confirmation of clear cell or non-clear cell RCC, ≥1 measurable baseline lesion as per RECIST criteria, Karnofsky performance status ≥70%, and adequate liver, renal, and bone marrow function are targeted for enrollment. Patients who have received prior systemic RCC therapy (sunitinib, sorafenib, bevacizumab, sirolimus, temsirolimus, everolimus, deferolimus) other than cytokine therapy are excluded. Everolimus 10 mg/d will be administered orally until disease progression, unacceptable toxicity, or study discontinuation for any other reason. The primary study endpoint is PFS. Overall survival, disease control rate, objective response rate and duration, and safety will also be assessed. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Novartis" @default.
- W2265434527 created "2016-06-24" @default.
- W2265434527 creator A5034618262 @default.
- W2265434527 creator A5041629403 @default.
- W2265434527 date "2010-05-20" @default.
- W2265434527 modified "2023-09-25" @default.
- W2265434527 title "Open-label phase II trial of everolimus monotherapy in patients with recurrent metastatic and/or unresectable renal cell carcinoma (RCC)." @default.
- W2265434527 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.tps233" @default.
- W2265434527 hasPublicationYear "2010" @default.
- W2265434527 type Work @default.
- W2265434527 sameAs 2265434527 @default.
- W2265434527 citedByCount "0" @default.
- W2265434527 crossrefType "journal-article" @default.
- W2265434527 hasAuthorship W2265434527A5034618262 @default.
- W2265434527 hasAuthorship W2265434527A5041629403 @default.
- W2265434527 hasConcept C121608353 @default.
- W2265434527 hasConcept C126322002 @default.
- W2265434527 hasConcept C143998085 @default.
- W2265434527 hasConcept C183713625 @default.
- W2265434527 hasConcept C185592680 @default.
- W2265434527 hasConcept C190283241 @default.
- W2265434527 hasConcept C2776694085 @default.
- W2265434527 hasConcept C2776820818 @default.
- W2265434527 hasConcept C2777472916 @default.
- W2265434527 hasConcept C2777802072 @default.
- W2265434527 hasConcept C2777921159 @default.
- W2265434527 hasConcept C2778019345 @default.
- W2265434527 hasConcept C2778695046 @default.
- W2265434527 hasConcept C2779490328 @default.
- W2265434527 hasConcept C2779699572 @default.
- W2265434527 hasConcept C2779984678 @default.
- W2265434527 hasConcept C2781230642 @default.
- W2265434527 hasConcept C31760486 @default.
- W2265434527 hasConcept C535046627 @default.
- W2265434527 hasConcept C55493867 @default.
- W2265434527 hasConcept C71924100 @default.
- W2265434527 hasConcept C86554907 @default.
- W2265434527 hasConceptScore W2265434527C121608353 @default.
- W2265434527 hasConceptScore W2265434527C126322002 @default.
- W2265434527 hasConceptScore W2265434527C143998085 @default.
- W2265434527 hasConceptScore W2265434527C183713625 @default.
- W2265434527 hasConceptScore W2265434527C185592680 @default.
- W2265434527 hasConceptScore W2265434527C190283241 @default.
- W2265434527 hasConceptScore W2265434527C2776694085 @default.
- W2265434527 hasConceptScore W2265434527C2776820818 @default.
- W2265434527 hasConceptScore W2265434527C2777472916 @default.
- W2265434527 hasConceptScore W2265434527C2777802072 @default.
- W2265434527 hasConceptScore W2265434527C2777921159 @default.
- W2265434527 hasConceptScore W2265434527C2778019345 @default.
- W2265434527 hasConceptScore W2265434527C2778695046 @default.
- W2265434527 hasConceptScore W2265434527C2779490328 @default.
- W2265434527 hasConceptScore W2265434527C2779699572 @default.
- W2265434527 hasConceptScore W2265434527C2779984678 @default.
- W2265434527 hasConceptScore W2265434527C2781230642 @default.
- W2265434527 hasConceptScore W2265434527C31760486 @default.
- W2265434527 hasConceptScore W2265434527C535046627 @default.
- W2265434527 hasConceptScore W2265434527C55493867 @default.
- W2265434527 hasConceptScore W2265434527C71924100 @default.
- W2265434527 hasConceptScore W2265434527C86554907 @default.
- W2265434527 hasIssue "15_suppl" @default.
- W2265434527 hasLocation W22654345271 @default.
- W2265434527 hasOpenAccess W2265434527 @default.
- W2265434527 hasPrimaryLocation W22654345271 @default.
- W2265434527 hasRelatedWork W1984657347 @default.
- W2265434527 hasRelatedWork W1995193840 @default.
- W2265434527 hasRelatedWork W2014636539 @default.
- W2265434527 hasRelatedWork W2037837794 @default.
- W2265434527 hasRelatedWork W2058590603 @default.
- W2265434527 hasRelatedWork W2063672847 @default.
- W2265434527 hasRelatedWork W2099294889 @default.
- W2265434527 hasRelatedWork W2137381953 @default.
- W2265434527 hasRelatedWork W2154171266 @default.
- W2265434527 hasRelatedWork W2385876243 @default.
- W2265434527 hasVolume "28" @default.
- W2265434527 isParatext "false" @default.
- W2265434527 isRetracted "false" @default.
- W2265434527 magId "2265434527" @default.
- W2265434527 workType "article" @default.